We are live on ! Find out more
SFCM

Seven Fleet Capital Management Portfolio holdings

AUM $606M
This Fund
S&P 500
This Quarter Est. Return
+32.72%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$606M
AUM Growth
+$288M
Cap. Flow
+$198M
Cap. Flow %
32.7%
Top 10 Hldgs %
65.14%
Holding
138
New
23
Increased
43
Reduced
23
Closed
42

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$118M
2
TNGX icon
Tango Therapeutics
TNGX
+$67.4M
3
RVMD icon
Revolution Medicines
RVMD
+$23.6M
4
PHVS icon
Pharvaris
PHVS
+$18.2M
5
MIRM icon
Mirum Pharmaceuticals
MIRM
+$11.1M

Top Sells

Rank Stock Value
1
TYRA icon
Tyra Biosciences
TYRA
+$7.49M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.63M
3
PCVX icon
Vaxcyte
PCVX
+$4.27M
4
SLNO
Soleno Therapeutics
SLNO
+$3.88M
5
KALV
KalVista Pharmaceuticals
KALV
+$2.59M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Miscellaneous 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GERN icon
51
Geron
GERN
$810M
$1.35M 0.22%
1,057,228
+633,048
+149% +$892K
ANL
52
Adlai Nortye Group ADS
ANL
$1B
$1.3M 0.21%
+113,207
New +$1.38M
CRVS icon
53
Corvus Pharmaceuticals
CRVS
$977M
$1.24M 0.2%
82,890
– –
ALKS icon
54
Alkermes
ALKS
$6.85B
$1.22M 0.2%
23,285
-885
-4% -$34.6K
SYRE icon
55
Spyre Therapeutics
SYRE
$7.56B
$1.18M 0.19%
13,300
-6,390
-32% -$466K
CATX icon
56
Perspective Therapeutics
CATX
$288M
$1.13M 0.19%
332,613
-46,469
-12% -$176K
OKUR
57
OnKure Therapeutics
OKUR
$117M
$1.1M 0.18%
+240,963
New +$1.03M
SMMT icon
58
Summit Therapeutics
SMMT
$12.5B
$1.09M 0.18%
+73,300
New +$1.3M
ANTX icon
59
AN2 Therapeutics
ANTX
$184M
$1.01M 0.17%
208,946
+9,245
+5% +$39.8K
CTNM
60
Contineum Therapeutics
CTNM
$473M
$992K 0.16%
60,541
+33,487
+124% +$439K
TRVI icon
61
Trevi Therapeutics
TRVI
$2.05B
$833K 0.14%
45,598
+18,449
+68% +$268K
VYGR icon
62
Voyager Therapeutics
VYGR
$165M
$772K 0.13%
230,406
+115,203
+100% +$437K
IVA
63
Inventiva
IVA
$796M
$757K 0.12%
200,141
– –
ENGN icon
64
enGene Therapeutics
ENGN
$131M
$711K 0.12%
+411,065
New +$1.68M
LRMR icon
65
Larimar Therapeutics
LRMR
$320M
$704K 0.12%
230,921
-25,664
-10% -$102K
IKT icon
66
Inhibikase Therapeutics
IKT
$287M
$704K 0.12%
346,900
+21,300
+7% +$38.1K
NGNE icon
67
Neurogene
NGNE
$567M
$694K 0.11%
+22,060
New +$607K
IHI icon
68
iShares US Medical Devices ETF
IHI
$3.52B
$682K 0.11%
+13,800
New +$701K
SLN
69
Silence Therapeutics
SLN
$695M
$660K 0.11%
60,107
-96,652
-62% -$680K
KRYS icon
70
Krystal Biotech
KRYS
$10.2B
$659K 0.11%
1,774
-2,542
-59% -$760K
IRD
71
Opus Genetics
IRD
$396M
$588K 0.1%
143,137
+8,895
+7% +$41.5K
PALI icon
72
Palisade Bio
PALI
$253M
$569K 0.09%
272,204
+59,104
+28% +$116K
EOLS icon
73
Evolus
EOLS
$526M
$542K 0.09%
78,057
– –
UNCY icon
74
Unicycive Therapeutics
UNCY
$131M
$521K 0.09%
103,400
+47,700
+86% +$352K
CMPX icon
75
Compass Therapeutics
CMPX
$203M
$510K 0.08%
233,066
-283,906
-55% -$838K
1 2
3
4 5

Similar funds

NPPM
North Point Portfolio Managers Orange Village, Ohio $606M AUM 20.84% 1-Year Est. Return
SCM
SKBA Capital Management San Francisco, California $606M AUM 13.33% 1-Year Est. Return
BFC
Banc Funds Company Chicago, Illinois $605M AUM 26% 1-Year Est. Return
VV
Verbena Value Westport, Connecticut $605M AUM
CM
Conifer Management New York $607M AUM 29.07% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $605M AUM 17.2% 1-Year Est. Return
MCM
Mason Capital Management New York $607M AUM 1.77% 1-Year Est. Return
V
VeraBank Henderson, Texas $604M AUM 23.32% 1-Year Est. Return

Seven Fleet Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Seven Fleet Capital Management held 138 positions worth $606M, up 90% from $318M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Seven Fleet Capital Management deployed $198M of net new capital in Q2 2026, opening 23 new positions and adding to 43 existing holdings. Its largest new stake was Mirum Pharmaceuticals: 110,393 shares worth $12.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 56% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Agios Pharmaceuticals, an estimated $4.63M trimmed.

  • Seven Fleet Capital Management's largest Q2 2026 buy was Mirum Pharmaceuticals: 110,393 shares worth $12.9M.
  • Seven Fleet Capital Management added most to CG Oncology in Q2 2026, an estimated $118M increase.
  • Seven Fleet Capital Management's biggest Q2 2026 reduction was Agios Pharmaceuticals, cutting an estimated $4.63M.
  • Seven Fleet Capital Management fully exited Tyra Biosciences in Q2 2026, selling an estimated $7.49M.
  • Seven Fleet Capital Management's ten largest holdings make up 65% of its $606M portfolio in Q2 2026.
  • Seven Fleet Capital Management opened 23 new positions and closed 42 in Q2 2026.
  • Seven Fleet Capital Management's portfolio value rose 90% quarter-over-quarter to $606M.

Based on Seven Fleet Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.